Human Genome Sciences, Inc. Second Quarter Earnings Sneak Peek

Human Genome Sciences, Inc. (NASDAQ:HGSI) will unveil its latest earnings on Thursday, July 21, 2011. Human Genome Sciences, Inc. is a commercially focused biopharmaceutical company advancing toward the market with three products in late-stage clinical development. Investing in Healthcare: Dendreon, Eli Lilly, Roche and More>>

Human Genome Sciences, Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for net loss of 41 cents per share, a wider loss from the year earlier quarter net loss of 30 cents. During the past three months, the average estimate has moved up from a loss of 44 cents. Between one and three months ago, the average estimate moved up, and has risen from a loss of 42 cents during the last month.

Past Earnings Performance: The company is hoping to beat estimates after missing the mark for two straight quarters. Last quarter, it reported a loss of 69 cents per share against an estimate of net loss of 52 cents per share. The quarter before that, it missed forecasts by 7 cents.

Savvy Investing Tip: Our CHEAT SHEET investing framework recommends only stocks with two straight quarters of earnings growth. Learn More >>

Wall St. Revenue Expectations: On average, analysts predict $29 million in revenue this quarter, a decline of 25.2% from the year ago quarter. Analysts are forecasting total revenue of $168.6 million for the year, a rise of 7.1% from last year’s revenue of $157.3 million.

Analyst Ratings: Analysts are bullish on this stock with 14 analysts rating it as a buy, two rating it as a sell and two rating it as a hold.

Key Stats:

Revenue has fallen in the past two quarters. In first quarter, revenue declined 42.9% to $26.6 million from the year earlier quarter. In the fourth quarter of the last fiscal year, the figure fell 59.8%.

Competitors to Watch: GlaxoSmithKline plc (NYSE:GSK), Immunomedics, Inc. (NASDAQ:IMMU), Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA), Amgen, Inc. (NASDAQ:AMGN), Biogen Idec Inc. (NASDAQ:BIIB), AstraZeneca plc (NYSE:AZN), Merck & Co., Inc. (NYSE:MRK), Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), and Peregrine Pharmaceuticals (NASDAQ:PPHM).

Stock Price Performance: During May 18, 2011 to July 15, 2011, the stock price had fallen $5 (-17.7%) from $28.20 to $23.20. The stock price saw one of its best stretches over the last year between December 31, 2010 and January 12, 2011 when shares rose for nine-straight days, rising 12.9% (+$3.07) over that span. It saw one of its worst periods between April 27, 2011 and May 6, 2011 when shares fell for eight-straight days, falling 8% (-$2.38) over that span. Shares are down 69 cents (-2.9%) year to date.

(Source: Xignite Financials)

Get Actionable Investing Insights: Check Out Wall St. Cheat Sheet’s newest Feature Trades of the Month!